Opioid-Induced Respiratory Depression

The Anesthesia Patient Safety Foundation is committed to the safe and reliable administration of every anesthetic.  An area of concern has been respiratory depression in the immediate postoperative period secondary to narcotic administration.  The following information comes directly from the foundation;

The APSF believes that clinically significant, drug-induced respiratory depression in the postoperative period remains a serious patient safety risk that continues to be associated with significant morbidity and mortality since it was first addressed by the APSF in 2006.1 The APSF envisions that “no patient shall be harmed by opioid-induced respiratory depression in the postoperative period,” and convened the second multidisciplinary conference on this serious patient safety issue in June of this year in Phoenix, AZ, with 136 stakeholders in attendance. The conference addressed “Essential Monitoring Strategies to Detect Clinically Significant Drug-Induced Respiratory Depression in the Postoperative Period.”

Click here to read the full report by the APSF regarding drug-induced depression in the postoperative period.  After reading the report, click the back arrow to return to this site and leave a comment for your colleagues.

Ketamine Supplement for Anesthesia

Ketamine is an old drug which has come in and out of favor many times over the past decades.  Currently, articles are emerging touting the advantages of Ketamine as a supplement for  both general anesthesia and monitored anesthesia care.  Below is a description by Pamela Chambers, CRNA regarding her clinical experience using Ketamine as a supplement.  Read her excellent review, scan the articles and leave a comment to share your experiences with your colleagues.

Submitted by Pamela Chambers, CRNA

Lexterrae legal consulting service

For the EP case that lasted 6+ hours, GETA with .5 mac Desflurane and Propofol infusion at 30 ug/kg/min, the Propofol Ketamine mixture performed very well.  I mixed 50mg Ketamine in each 50ml bottle of propofol.  I used less than 3 bottles for the case and never used more than .5 mac Des.  I used a total of 25 ug Fent, just after intubation, for the case.  The patient was 83 yo male, approx 90 kg, EF 20%.

Upon emergence the patient denied any pain or discomfort.  He was appropriately responsive to verbal and did not cough on extubation. VS were stable and he was A&O x3 on arrival to the EP room for phase 2 recovery.

A few days later, I used Ketamine as an analgesic adjunct for another long case (10 hr bilateral mastectomy and tram flap).  I used a total of 195 mg Ketamine.  The patient was an ASA 1.  After 100 ug Fent (and 3mg Versed) prior to induction, I used 30 mg Ketamine approximately 3 mins prior to incision.  Then I administered 30 mg Ketamine at hr number 2, and hr #3.  Around hr #4, I decreased the Ketamine to 15mg for each hrs successive dose with a plan to halt Ketamine admin when I believed the case was 2 hrs from completion.  My last Ketamine dose was at 1430 during the last phases of the case. The patient began spontaneous ventilations after reversal of NDMR at approximately 1640.  The case ended at approximately 1730.  The patient

received a total of 2200 ug Fent dosed approximately 100 ug every 30-45 mins.

Intermittent rescue doses for SNS spike were not required. Pressor agents were not used. Hemodynamics were extremely stable, almost like the proverbial railroad track!

Total fluid administered was 2 liters NS and 1 liter 5% Albumin, UO was 150 ml, EBL 300ml. I also adminstered 2 mg Versed at 1600 to facilitate decreasing the inhaled agent level and to ameliorate any emergence delirium associated with the Ketamine.  The patient was appropriately responsive to verbal prior to extubation, and did not cough during extubation.  She also denied any c/o pain immediately post-operatively. No emergence delirium was appreciated.

Click here to read a review article by Laskowshi et. al regarding Ketamine use

Click here to read an article by McCartney et al regarding the role of the NMDA receptor

The Sticky Situation of Adhesion

Submitted by Pamela Chambers, MSN, CRNA, EJD

Click here for Lex Terrae consulting

Two years ago, Joe Sixpack was admitted to your facility to undergo vasectomy.  His clinical course in your fine medical center was uneventful. Today, you are seated in the office of the facility mediator and all relevant parties are present: Joe Sixpack, Mrs. Sixpack, little baby Sixpack who will celebrate his first birthday next week, and everyone involved in the clinical care of Mr. Sixpack on that fateful day 2 years ago.

Before beginning the mediation process, the facility’s attorney presents the admitting forms that Joe signed upon arrival to the facility and prior to receiving any sedation for his procedure.  One of the forms, a two sided form, contains an explanation of the procedure that Joe has requested on side one, along with the risks, benefits, and options of the procedure and several blank lines at the bottom of the form in case Joe wanted to add anything to the form. Side two of that same form contains the following statement “I hereby release Smallville Medical Center and it’s employees and contractors, from all liability arising from any injury to me resulting from my requested therapeutic procedure to be performed by Dr. Kuttemup and his staff at Smallville Medical Center.”  Immediately after this paragraph is Joe’s signature with the date and time the form was signed.

When a healthcare provider has this type of statement in a contract for services for the express purpose of limiting liability relating to the provision of those services, this is termed an exculpatory clause.  When this type of clause is a condition to obtaining the requested service this creates a contract of adhesion. While most courts attempt to enforce contracts by trying figure out what the parties intended when the contract was written; courts often find contracts of adhesion unenforceable as a matter of public policy (Weaver v. American Oil Co., 257 Ind. 458, 276 N.E.2d 144 (1971).

The contract to provide health care services is not usually between 2 similarly situated (i.e. equally knowledgeable) parties.  If a contract is deemed grossly unfair to one party it will usually be held unenforceable in court.  Consider the following release from Olson v. Molzen (558 S.W. 2d 429, Tenn., 1977) “…I therefore release Dr. Molzen and his staff from responsibility associated with any complications that may come up or be apparent in the next 12 months…”  The court in this case found the exculpatory clause particularly distasteful because an individual in such a profession, a physician, should not be permitted to hide behind such a shield as a license to commit professional negligence.

Regarding all contracts, there lies a duty to read.  This is small comfort to a plaintiff but a court will evaluate the parties intent to contract by evaluating the terms of the contract.  Terms that appears grossly unfair (i.e. unconscionable), violate public policy (i.e. one cannot receive the healthcare service with out agreeing to the term), or lack true assent will likely lead to a ruling that the contract is unenforceable.

About the author:  Pamela Chambers is a staff CRNA a Central Texas regional trauma center and the affiliated Children’s hospital. Ms Chambers received her MSN in 2000 while on active duty in the U.S. Army; then received her Executive Juris Doctor (EJD) in Health Law in 2008 from Concord Law School. Ms. Chambers owns Lex Terrae Consulting a health law research and consulting firm and also teaches Legal Nurse Consulting for Kaplan University. Ms. Chambers is not an attorney. The information provided is legal research and should not replace consultation with an attorney or physician when warranted.

DNR in the Operating Room

You are scheduled to do a patient coming from the ward with Do Not Resuscitate orders.  What does that mean and what do you do?  Some would argue that General Anesthesia is a controlled resuscitation on every case, and, therefore either the DNR orders should be suspended or the case should be canceled.   Does that choice afford the patient the quality care that he/she expects and deserves?

Across the nation, patients with terminal conditions come to the operating room for procedures that will not extend their lives but will improve the quality of life.  Stabilization of a pathologic fracture or the insertion of a feeding tube are but two examples.   Click here to read the excellent review of DNR in the operating room from the University of Washington Medical School and then come on back to www.procrna.com.   Leave a comment and share your thoughts with your colleagues

LMA in the Prone Position

The LMA (Laryngeal Mask Airway) has been a common airway management device used by the Anesthesia community for two decades.  Because the device does not “secure” the airway like a cuffed endotracheal tube would, anesthetists are selective about the patient population and type of surgery when deciding whether or not to use the LMA.  Our international colleagues seem to have been bolder with the use of the LMA and report its use in the lateral and sitting positions.   An Article by Ng Published in Anesthesia and Analgesia reported a series of over 200 patients who were safely induced in the prone position with the LMA inserted after induction.  Click here to read the article and then return to procrna.com and leave a comment.  Let us know about your experience using the LMA in the non-supine patient.

ivNOW Fluid Warmer

Patient temperature at the end of the case is an important marker of compliance with SCIP indicators of quality anesthesia care.  Achieving the goal of temperature maintenance in the anesthetized patient requires the use of several techniques including warm blankets, forced air warming, the use of a HME in the breathing circuit, and the administration of warm fluids.

To assist the anesthetist with patient warming, Enthermics has developed the ivNOW fluid warmer.  Each cavity has a control and L.E.D. display. A sensor in the heating plate detects the presence of a bag and engages the heating mechanism to quickly warm the fluid. Two temperature sensors continuously read the temperature of the fluid bag to engage the heater as necessary to maintain the fluid temperature within +0/-2ºC (+0/-3ºF) of the set point temperature. The electronic control monitors the length of time the bag has been held at temperature, displayed additionally by a status button. The control alerts users when a fluid bag has been held at temperature longer than 14 days.

Click here to go to the ivNOW web site and review the manufacturer’s product information.  If you have experience with this product, please leave a comment on PROCRNA.com and share your experience with your colleagues.

Res Ipsa Loquitur

This is a theory of liability that basically states “the thing speaks for itself”.  This doctrine is applied in medical malpractice usually in cases where the injury is in a location of the body distinct from the proposed procedure or operation.  The classic case is Ybarra v. Spangard, 25 Cal.2d 486, 154 P.2d 687 (1944), here the plaintiff underwent an appendectomy but awoke from surgery with pain in his arm.  The court applied Res Ipsa Loquitur to the facts, finding (in part), “the defendant had control at one time or another the of…instrumentalities which might have harmed the patient…”

 

Three conditions must be met for application of this doctrine: The accident must be the kind that does not ordinarily occur in the absence of someone’s negligence; it must be caused by an agency or instrumentality within the exclusive control of the defendant; and it must not have been due to any voluntary action or contribution on the part of the plaintiff. Dobbs, The Law of Torts Sect 249 (2000).

 

Some courts have resisted use of this doctrine because of concern that healthcare providers would be in constant fear of liability from rare bad outcomes.  In Siverson v. Weber, 57 Cal2d 834, 22 Cal.Rptr 337 P.2d 97 (1962) the court acknowledged this doctrine would place an undue burden on the medical profession and limit the use of innovations even if due care is exercised.

 

Some states allow a jury to infer negligence vis-à-vis Res Ipsa, others treat the doctrine as a presumption that a defendant must rebut.  Appropriate review of recent caselaw is prudent for defense against this type of allegation.

Clean Machine for MH patients

What do you do when you learn that your next patient is MH succeptible?  Do you have “clean machine” sitting in the store room or do you change the absorber, turn up the flows and let the machine air out?  Studies have shown that it can take over an hour of high flow to sufficiently reduce the residual gas in the machine to acceptable levels.  Vapor clean is a product which eliminates trace gases from the circuit immediately.

Prepare Any Anesthesia Machine for Susceptible Patients in Less than 60 Seconds

Newer anesthesia gas machines contain plastic and elastomeric components that absorb volatile anesthetics and then release residual vapor during subsequent anesthetic procedures.  The anesthesia gas machine requires high flows  and  a lengthy time period to remove most of the vapor  before the machine can be used for a patient that cannot tolerate breathing trace amounts of volatile anesthetic vapor.  The Vapor-Clean filters absorb the trace amounts of isoflurane, sevoflurane and desflurane so that anesthetic vapors do not reach the patient.

Placement of the Vapor-Clean filter canisters on the anesthesia machine allows the machine to be immediately vapor-free (less than 5 parts per million of vapor).

Click here to go to the manufacturer’s web site and review the product information.  If you have used this product or have any other information to share regarding safe administration of anesthesia to MH patients, leave a comment.

Texas Assn. State Meeting

Once again, the Texas Association of Nurse Anesthetists has hosted an excellent State meeting.  Held at the Marriott Legacy Town Center in Plano Texas, CRNAs from around the state gathered for 3 days of quality presentations.  Both CRNAs and Anesthesiologists presented topics of interest to both practice and policy.  John McFadden presented a Region 7 update and Michael Rieker presented an update regarding the proposed recertification exam.  Academic topics ranged from new product review to clinical practice topics.  All in all, this was an excellent meeting.  Don’t miss the spring meeting February 17-19 at The Woodlands, Texas.

ultrasound visualization

CRNAs and Anesthesiologists  worldwide are using ultrasound visualization to improve patient safety, increase efficiency and decrease complications. SonoSite works closely with anesthesiologists to develop customized solutions that meet the rapidly expanding clinical requirements. Advanced needle visualization is just one example of our forward-thinking product enhancements. Advanced needle visualization makes the needle clearly distinguishable while maintaining striking image quality of the target and surrounding anatomy—especially at the steep angles needed on common procedures such as deep femoral blocks.

Click here to go to the manufacturer’s web page and learn about the Sonosite system.  If you have experience with the product, please leave a comment and tell us about your experience.

Strictly Speaking

Most of us take comfort in the fact that each day that we come to work to serve our patients, we intend to perform at our very highest caliber.  We hope that our stellar reputations will shield us from liability if anything unplanned should occur and injury befalls a patient.  Well, strictly speaking – this just isn’t the case.

Strict liability is a theory in which fault can be determined regardless of intent or even knowledge of wrongdoing. 

Strict liability can apply to crimes or torts. An example of a strict liability crime is the act of serving alcohol to minors. Strict liability in tort is generally focused on objects (not actors) that cause harm (i.e. strict products liability).

To prevail in a cause of action based on strict products liability (SPL), the plaintiff must prove: 1) the product was defective, 2) it was defective when it left the defendants hands, and 3) the defect was the proximate cause of the harm suffered.  It is also necessary that the product be expected to and does reach the consumer without substantial change from it’s condition when sold.  Liability will attach if a product is sold in a defective condition and the defect causes a foreseeable user of the product to suffer personal injury as a result; any party involved in the commercial supply of that product will be held strictly liable for the injury.  Mandatory considerations in a SPL cause of action include: 1) proper plaintiff (any user or consumer), 2) proper defendant (any entity in the marketing chain, not occasional or used dealers), 3) proper context (personal or property harm not harm to the product), 4) defect type (manufacturing, design, or warning), 5) cause in fact (“but for” the defect the plaintiff would not have been injured), 6) proximate cause (the harm was reasonably foreseeable from the defect; no superceding conduct present – like misuse or alteration of the product), and 7) actual harm.  A product is considered “defective” if based on it’s design, manufacturing, or lack of adequate warning it constitutes a danger to the average consumer that is greater than the social utility of the product.

So you may be thinking, you are safe from this type of liability because you NEVER intend to harm any of your patients or use any defective equipment.  But what if a patient has an injury after surgery that they did not have before surgery, and the injury is such that they could not have contributed to its occurrence and last, but not least, the injury stems from a modality that was under your (the anesthesia provider) exclusive control……Res Ipsa Loquitur – The thing speaks for itself.

Pamela Chambers, MSN, EJD

Remifentanil

Remifentanil is a lesser known and used rapid onset / rapid elimination narcotic.  Despite the advantage of prompt elimination when the infusion is stopped, this valuable drug has not been aggressively marketed.

Recently, the ownership of Remifentanil has been transferred to Mylan Institutional.  With the new ownership has come new marketing to educate anesthesia providers about the safe use of the drug, especially during TIVA procedures.

Click here to go to the Ultiva web site and view their instructional information. If you have experience with this drug, please write a review to share with your colleagues.

Evidence Spoilage

Submitted by Pamela Chambers, CRNA, MSN, EJD

As we continually strive to provide the highest level of patient care to the guests in our facility, we cannot help but learn from the mistakes of others.  In an article published in the Dallas Morning News regarding the CMS findings at Parkland Hospital, one issue (of many) struck me as something many of us may not think about on a daily basis as we provide patient care. Document preservation, a.k.a. evidence preservation.

As electronic medical records, storage, and retrieval becomes the norm across the nation, all healthcare providers must be vigilant to not only document the care that is provided – but also produce any records about that care that are requested pursuant to any legal action in a timely manner.  Unreasonable (re: any) delay in production of records can have harsh adverse consequences.

SPOLIATION: the intentional destruction, mutilation, alteration, or concealment of evidence… If proven, spoliation may be used to establish that the evidence was unfavorable to the party responsible. (Black’s Law Dictionary, 8th Ed.)

While discovery is the process of collecting information to support the allegations and to otherwise build a case; Electronic discovery (E-discovery) is the collection, preparation, review, distribution, and production of electronic documents in litigation discovery. Electronic discovery includes files stored on office CPUs, laptops, network servers, Personal Digital Assistants (PDAs),CDROMs, DVD-ROMs, MP3 players, smart cell phones, backup tapes, flash memory cards and devices, other archive media, and third party storage systems. Also, voice mails become digital evidence, as collectable as e-mail. All of this digital content can become an important part of litigation.

During 2003 and 2004, United States District Court Judge Shira A. Scheindlin issued five groundbreaking opinions in the case of Zubulake vs UBS Warburg LLC.  Zubulake involved a typical employee discrimination claim, alleging gender discrimination and retaliation. The defendant produced approximately 100 pages of e-mails pursuant to the plaintiff’s request for production of all relevant documents but failed to search its backup tapes for e-mails that may have been deleted or stored elsewhere. Since the plaintiff had saved more than 400 e-mails herself, she knew the defendant did not produce all relevant information. Zubulake’s attorney was permitted to argue to the jury that the defendant intentionally destroyed incriminating documents. Ultimately, the court found that the defendant had deleted emails, lost backup tapes, and failed to diligently and thoroughly produce all its relevant files.

The court penalized the defendant by allowing an “adverse inference” instruction to the jury, noting that the jury could assume that the missing documents contained information adverse to the defendant’s case. In the end, the plaintiff was awarded more than $29 million in damages.

A party to litigation, or to litigation that is reasonably foreseeable, has a duty to preserve evidence in its possession or control that may be relevant. Adequate preservation of electronic stored information (ESI) requires more than simply refraining from efforts to destroy or dispose of such evidence. The party must immediately intervene to prevent loss due to routine operations or malfeasance. If a party destroys evidence in its custody or control, it can be subject to sanctions that range from an assessment of costs and fees to suppression of evidence, an adverse jury instruction, or even dismissal of the case.

Food for thought…….

Promises, Promises

Submitted by Pamela Chambers, CRNA, MSN, EJD

A guy walks into a bar… he says to the guy next to him, “My laryngoscope is bigger than your laryngoscope”.  Unbeknownst to guy #1, guy #2 was a surgeon and was offended to be mistaken for an anesthetist.  So guy #2, Dr. Alice, punches guy #1, Dr. Guedel, in the jaw.

Now Dr. Alice has an injured and deformed right hand.  He goes to see his friend Dr. Adson – the plastic surgeon.  Dr. Adson observes how distraught Dr. Alice is and tells him he can indeed fix his injured hand.  Dr Adson tells Dr. Alice that he can give him a good hand so that he can return to surgery.

During the procedure, Dr. Adson realizes he must apply a skin graft to effectively correct Dr. Alice’s injured hand.  The operative consent gives Dr. Adson permission to use a skin graft if necessary during the procedure.  Dr. Adson obtains skin from Dr. Alices’s chest for use in the skin graft.

Days later, Dr. Alice returns to see Dr. Adson for a follow-up visit and to have his bandages removed.  Both doctors observe hair growing from the grafted skin that now is growing on Dr. Alice’s right hand.   Dr. Alice is distraught and decides to sue Dr. Adson.  But under what theory?  If a malpractice suit is filed, Dr. Adson would have to establish negligence and all of the required elements necessary to sustain such a theory.  Additionally, expert witness testimony would be needed to establish standard of care and the deviation from it if present.

Dr. Alice sued Dr. Adson for breach of contract.  Dr. Adson promised Dr. Alice “a good hand”, presumably that meant a hand free of hair.  Does this sound absurd?  Well a contract claim can be more advantageous in some circumstances over a malpractice claim.  Why?  Because, the remedy that is awarded in a contract claim is the difference between what was promised in the contract and what is present.  There is no question of wrongdoing, no questions of standards of care, and no pesky expert witness.   When there exists a dispute as to the terms of a contract, courts try to interpret contracts based what the parties intended at the time of the agreement.  In Guilmet vs. Campbell, 385 Mich.57. 188 N.W.2d 601 (1971), a jury found for the plaintiff under a breach of contract theory. In this case the surgeon promised a particular result. The patient suffered severe postoperative after-effects – which were very different from the promise of “it’s a very simple operation… you’ll be out of work 3-4 weeks at most”.

As with all areas of jurisprudence, the measure of damages in a breach of contract suit can be computed various ways.  Expectancy damages would be some amount that would place the plaintiff in the position that he would have had if the contract had been performed as promised.  Whereas restitution damages would be an amount equivalent to the benefit conferred upon the defendant by breaching the contract.  In Sullivan vs. O’Connor, 363 Mass.579, 296 N.E2d 183 (1973) the court decided to compute damages using an intermediate method – reliance damages.  In Sullivan, the plaintiff recovered expenditures and costs that he bore as a result of the defendant’s breach of their contract.

Who said the only contracts in the hospital were the ones in administration??

Belmont Rapid Infusion System

The Belmont Rapid Infusion System has had wide use by the Military in the Middle East war.  The system enables the rapid delivery of large volumes of warmed fluid during a resuscitation.   The following testimonial was reported on the manufacturer’s web site:

Soldiers are Alive Today Because of the Belmont
“We were able to sustain their lives long enough so the surgeons could fix them. When we were in Baghdad we pumped over 100 units of blood products through the Belmont on this single patient,and ten years ago…he would not have lived.”

This rapid infusion system is gaining popularity in trauma centers throughout the United States.  Again, a testimonial from the manufacturer’s web site:

The Anesthesiology Practice at a Major New York Metro Area Medical Center
“Switched from the Level 1 to the Belmont Rapid Infuser about three months ago. We purchased two, one for our main O.R. and one for Obstetrics. We have already used it in a case requiring more than 32 units of blood. It was flawless and clean.”
Major New York Metro Area Medical Center

For more information about the infusion system, click here to go to the manufacturer’s web site.

PROCRNA.COM would like to hear from those using the Belmont Rapid Infusion System.  How is it working for you?  Leave a comment and help your colleagues who are in need of a rapid infusion system.

LMA Supreme

Over the past 20 years the LMA has earned it’s place among the options for quick, safe, and easy airway management.

Improving upon existing technology, the LMA Supreme has been introduced to the marketplace.  The integrated drain tube allows fluids to channel away from the airway and the integrated bite block ensures airway integrity if the patient bites down.

PROCRNA.com would like to hear from those who are using this product.  Click here to view the manufacturer’s information regarding the LMA supreme.  After reviewing the information, return to this site and leave a comment.

NBCRNA Recertifican Exam proposal

The following message comes from the NBCRNA regarding the proposed recertification exam for CRNAs:

At the AANA Annual Meeting in Boston, the NBCRNA unveiled a draft of the Continued Professional Certification (CPC) program developed over the past three years. The intent of the recertification process is to ensure that the CRNA credential represents an acknowledged commitment to excellence, and continues to distinguish us from others in the field.

The proposal is in draft form. To accommodate major changes to our website, the official comment period for the proposed changes is scheduled to start September 6, 2011 and runs through November 14, 2011. However, many of you already have written us with questions and comments, some supportive, others challenging the need for change, and most simply asking for more information. We have posted answers to the most frequently asked questions at www.nbcrna.com. We welcome your thoughts prior to the official comment date via email at recertification@nbcrna.com.

The NBCRNA understands your concerns about changes to the recertification process and wants to reassure you that the proposed recertification exam will NOT be similar to the rigorous entry level certification exam. The recertification exam will evaluate clinically relevant knowledge in which all certified registered nurse anesthetists must be proficient regardless of their practice setting. These areas include 4 core competencies: airway management, pharmacology, pathophysiology and anesthesia technology. The recertification exam will contribute to ensuring that those who hold a CRNA credential are seen as committed to being the best educated, best prepared workforce possible.

The proposed changes would go into effect in 2015, and the first recertification exam will be available in 2019. Those individuals who are planning to retire by the end of 2023 will not be required to take the recertification examination. To assure constituents fully understand both the goals and specifics of the program as drafted, we will shortly announce a series of web based town hall meetings to give people an additional opportunity to discuss the proposed changes in the Continued Professional Certification program. We look forward to your participation and receiving your input.

Prevention of Intraoperative Awareness in a High-Risk Surgical Population

To Bis or not to Bis….the controversy continues.  A study reported in the New England Journal of Medicine (Avidan et al, August 18,2011) evaluated using BIS versus end tidal agent concentration in the prevention of intraoperative awareness.

In this study, 6041 patients were randomly assigned to either have BIS or end tidal agent to determine anesthetic depth.  After surgery patients were assessed regarding intraoperative awareness.

Findings were that the superiority of BIS was not established and fewer patients had awareness in the end tidal agent group than in the BIS group.

Click here for article

In the same issue of NEJM, an editorial by Gregory Crosby, MD reviews the evolution of patient monitoring with regard to awareness and cautions that end tidal agent in and of itself may not be the answer to the problem.

Click here for editorial

Review the original article and make a comment….to Bis or not to Bis, that is the question.

AANA National Meeting, Boston

The AANA National meeting was held in Boston August 6-10.  Once again, the meeting exceeded all expectations.  The host City of Boston was welcoming to the visitors from across the country and offered many attractions for CRNAs in attendance.

Educational sessions were organized and presented by the top CRNA speakers from across the country.  Topics were relevant to practice and presented in a professional manner.

My best memory of the meeting was the number of top quality people in our association who give of themselves on a daily basis to make a difference in the life of our patients and the life of our organization.

Attendance at the National Meeting is a must at least one time for every CRNA.  See you in San Francisco 2012.

Medication vial label study

The United States Pharmacopeia is sponsoring a research study concerning the usage and disposal terms on injectable medication vial labels. The objective of the study is to acquire input from professional healthcare providers on possible changes to the terms on the label describing the use and disposal of the drug product.

The AANA and other professional organizations respectfully request your participation in this research study, as your input may help improve the clarity of terms used on labels and improve the safe use of injectable drug products in the future.

This brief survey should take no more than 10 minutes of your time.

Please click here to participate in the study

Northwest Anesthesia Seminars, Waikiki meeting

Overall, a great meeting in a great location. The theme for the meeting was trauma and the speakers were knowledgible. There were excellent reviews of mechanisms of trauma as well as airway management and fluid replacement. The review of the massive transfusion protocol, including the type and volume of fluid to be given, was informative. I was satisfied with the meeting and would return to Waikiki for another meeting.

Reviewed by TD in Texas

Risks of Anesthesia Care in Remote Locations

From the ASPF Newsletter

Patients receiving anesthesia in remote locations tend to be older and sicker than those in the Main OR.  In addition, they tend to receive MAC anesthesia more frequently.  Below is a case scenario.  Read the entire article from the ASPF newsletter and add your comments.

A 75-year-old, 100-kg, ASA 2 man was scheduled for endoscopic retrograde cholangiopancreatography (ERCP) under monitored anesthesia care (MAC). Monitors, including pulse oximetry, blood pressure, and ECG, were placed and the patient was turned prone for the procedure. He was given midazolam 2 mg and fentanyl 50 mcg IV, and he remained anxious. Additional midazolam 2 mg and fentanyl 150 mcg IV were given, but the patient could not tolerate insertion of the endoscope. Propofol 20 mg IV, followed by an infusion of 50-70 mcg/kg/min, was administered, and the procedure was begun with O2 saturations 88-92% on 4 L/min O2 by nasal prongs. After 20 minutes, the O2 saturation decreased to 70%, and the patient became severely bradycardic, and was treated with atropine 1 mg. Attempts at bag-mask ventilation and placement of a laryngeal mask airway failed. Blood pressure was not obtainable and the procedure was aborted. It took 2-3 minutes to push aside the heavy endoscopy equipment, move in a gurney, and turn the patient supine to begin CPR. Although the patient was resuscitated after 10 minutes of CPR, he sustained severe anoxic brain damage, and life support was eventually discontinued.

Cost Effectiveness Evaluation of Anesthesia Providers

Anesthesiologists and certified
registered nurse anesthetists
provide high-quality, efficacious
anesthesia care to the U.S.
population.

This research and analyses
indicate that CRNAs are less
costly to train than anesthesiologists
and have the potential for
providing anesthesia care efficiently.

Anesthesiologists and CRNAs
can perform the same set of
anesthesia services, including
relatively rare and difficult procedures
such as open heart
surgeries and organ transplantations,
pediatric procedures,
and others.

CRNAs are generally salaried,
their compensation lags behind
anesthesiologists, and they
generally receive no overtime
pay.

As the demand for health care
continues to grow, increasing
the number of CRNAs, and permitting
them to practice in the
most efficient delivery models,
will be a key to containing costs
while maintaining quality care.

Read the Full article in Nursing Economic$, 2010;28(3):159-169.

An overview of OFIRMEV

First and only IV acetaminophen in the US

  • Indicated for the management of mild to moderate pain; management of moderate to severe pain with adjunctive opioid analgesics; and reduction of fever
  • For adults and children ≥2 years old2

Comprehensive clinical dataset

  • The approval of OFIRMEV is supported by the results of 20 clinical trials involving 1375 patients1,2
  • IV acetaminophen has been studied in randomized clinical trials across a variety of surgical contexts and patient types1,3-5

Improved pain relief, reduced opioid consumption3

  • In total hip/knee replacement surgery, OFIRMEV 1 g + PCA* morphine demonstrated significant pain relief and reduced opioid consumption compared to placebo + PCA morphine3
  • The clinical benefit of reduced opioid consumption was not demonstrated

Patient satisfaction3

  • The hip/knee replacement study also showed that OFIRMEV 1 g + PCA morphine significantly improved patient satisfaction compared to placebo + PCA morphine†3

Significant fever reduction1

  • In adults with fever, antipyretic onset of action was significantly faster and duration of effect significantly longer with OFIRMEV than with placebo1

Established safety profile and well tolerated in clinical trials1-5

  • OFIRMEV was shown to be well tolerated in clinical trials1-5
  • The safety of IV acetaminophen has been monitored through a postmarketing surveillance program, with more than 400 million doses distributed since its European approval1
  • IV acetaminophen has been used outside the US since 2002 and is approved in over 60 countries1

Dosing for adults and children ≥2 years old2

  • OFIRMEV has a well-described pharmacokinetic profile2
  • Dosing guidelines have been established for children ≥2 years old through adults2
  • OFIRMEV is the first IV analgesic and antipyretic agent approved for children ≥2 years old2

Indication

OFIRMEV is indicated for the management of mild to moderate pain; the management of moderate to severe pain with adjunctive opioid analgesics; and the reduction of fever.

Important Safety Information

Do not exceed the maximum recommended daily dose of acetaminophen.

Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death.

OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation.

Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment.

OFIRMEV should be administered only as a 15-minute infusion.

Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur.

Do not use in patients with acetaminophen allergy.

The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients

The antipyretic effects of OFIRMEV may mask fever in patients treated for postsurgical pain.

To report SUSPECTED ADVERSE REACTIONS, contact Cadence Pharmaceuticals, Inc.
at 1-877-647-2239 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References: 1. Data on file. Cadence Pharmaceuticals, Inc. 2. OFIRMEV™ (acetaminophen) injection prescribing information. 3. Sinatra RS, Jahr JS, Reynolds LW, Viscusi ER, Groudine SB, Payen-Champenois C. Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery. Anesthesiology. 2005;102:822-831. 4. Atef A, Fawaz AA. Intravenous paracetamol is highly effective in pain treatment after tonsillectomy in adults. Eur Arch Otorhinolaryngol. 2008;265:351-355. 5. Memis D, Inal MT, Kavalci G, Sezer A, Sut N. Intravenous paracetamol reduced the use of opioids, extubation time, and opioid-related adverse effects after major surgery in intensive care unit. J Crit Care. 2010;25:458-462.

*Patient-controlled analgesia.
†Subjects were asked to evaluate the study treatments, overall, using a 4-point categorical scale.

Adobe® Reader® is required to view PDFs. If your computer does not have it installed, download it free here.

This site is intended for US healthcare professionals only.

Keeping Hydrated

by SCOTT & WHITE STAFF on JUNE 13, 2011in HEALTH AND WELLNESS 

Written By: Jenny Kidd, RD, LDThe Central Texas heat is well on its way so it’s that much more important to stay hydrated.  Water is crucial to physical health and makes up about 60% of body weight in adults and more in children. Body water balance is key for maintenance of body temperature, blood volume, and several metabolic processes. 

Most fluid recommendations suggest >3 liters per day for men and >2 liters per day for women. Other factors requiring additional fluid intake include:

  • Increased activity level
  • Increased sweat level
  • Living in a hot and humid environment
  • Living in high altitude
  • Pregnancy/Breastfeeding
  • Fever
  • Vomiting/diarrhea

While water is the most plain and obvious hydration source, other foods and beverages also contain significant amounts of water to contribute to overall hydration.  Many fruits and vegetables contain 70-90% water. Some of the best sources of water in food include:

  • Apples
  • Oranges
  • Grapes
  • Strawberries
  • Tomatoes
  • Watermelon (a summer favorite)
  • Potatoes
  • Corn
  • Broccoli
  • Spinach
  • Lettuce
  • Celery

Even many meats and cheeses contain more than 50% water. While water is typically the best choice, other beverages including skim milk and fruit juice are >90% water. Caffeinated beverages – tea, coffee, sodas and the like will also contribute to total fluid intake, but can contribute significantly to caloric intake. If you have a hard time drinking plain water, look for low calorie beverages to help you meet your fluid goals. Try water with lemon or lime juice, unsweetened tea or artificially sweetened drinks.

Without adequate fluid intake, there is risk of dehydration. The first sign of dehydration is thirst. But don’t wait until you’re thirsty to start drinking fluids. Thirst means your body isn’t keeping up with fluids adequately and needs replenishment. Other symptoms of dehydration include weakness, dizziness, dry mouth, decreased (and more concentrated) urine output, confusion and sometimes a feeling of a pounding heartbeat.

Some medical diagnoses should be cautious of drinking excess amounts of water. Talk to your physician or dietitian if you have questions about your fluid intake.